Ann: Trading Halt, page-195

IF this is approved I'm going to have look really hard for where I went wrong. I think I'll struggle to see explanations on this forum though. Dachopper seems to have been the only one to try to go through things in technical scientific and statistical depth on the forum.

What I'll admit I don't properly have a detailed handle on though is the extent to which the FDA could give conditional approval - ie - approval but subject to completion of another trial after approval providing confirmation. Politically that could be tempting to them. But they resisted at ODAC to do what might have been politically easy but scientifically and statistically wrong.

Its also true I've not seen the detailed datasets that MSB could have provided to the FDA. And which the FDA would be obligated to examine critically and fairly.